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Abstract 
 
Background: TNF-α 308G/A polymorphism has been the subject of numerous 
studies, investigating its possible association to preeclampsia with conflicting results. 
Previous meta-analyses have found no association.  
Aim: To update the previous meta-analyses and provide a more comprehensive and 
reliable conclusion, by performing an exploration of all the possible genetic models 
of association and subgroup analyses based on disease severity and ethnicity/racial 
descent.      
Methods: A systematic literature search in MEDLINE and EMBASE databases was 
conducted through July, 2015. Fixed and random effects meta-analysis of the 
relevant genetic association studies was performed. 
Results: 17 eligible studies including 2042 preeclamptic patients and 3612 controls 
were identified. Overall analysis did not indicate a significant association between 
TNF-α 308G/A polymorphism and risk for preeclampsia, severe preeclampsia or 
eclampsia. However, subgroup analysis revealed an elevated risk for preeclampsia 
among Caucasians, who carry the A allele (FE OR: 1,47, 95% CI: 1,23 to 1,77 under 
the dominant model).  
Conclusion: The role of TNF-α 308G/A polymorphism in preeclampsia susceptibility 
needs to be reevaluated, as it may account for increased risk for preeclampsia in 
Caucasians. Future research should determine high risk populations, taking into 
account genetic, environmental and socioeconomic effects.  
Introduction 
Preeclampsia (PE) affects 5–8% of pregnancies worldwide, being one of the leading causes of 
maternal and fetal morbidity and mortality, even in developed countries [1]. Although PE 
has been the object of intensive research efforts, its precise etiology and pathogenesis 
remain unknown.  
The development of PE is influenced by both genetic and environmental risk factors, 
suggesting its multifactorial etiology [2]. However, emerging evidence increasingly supports 
an immunological basis in the pathogenesis of PE [3, 4]. PE is associated with placental 
disorder, endothelial cell dysfunction and systemic vasospasm. It seems that abnormal 
immune system activation interferes in the events leading to the former alterations [5, 6]. 
Adequate placentation requires remodeling of the spiral arteries in the decidua to allow 
adequate blood flow to the placenta [7, 8]. Placental invasion and development are 
dependent on tightly regulated local inflammatory processes [9, 10]. In particular, the 
interaction between fetal trophoblasts and maternal decidual cells is mediated by maternal 
natural killer (NK) and T-cell activity [5, 11]. Hence, inflammatory cytokines mediate normal 
placentation in a controlled inflammatory process typical of healthy pregnancy [12]. With PE, 
there is poor to absent vascular remodeling in the myometrium and decidua. Inadequate 
placentation results in hypoxia and ischemic–reperfusion injuries, which may lead to the 
release of inflammatory cytokines [8]. Excessive placental stimuli cause the exaggerated 
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systemic inflammatory response coupled with generalized endothelial dysfunction, which 
characterizes PE [3, 12]. Both the innate and adaptive arms of the immune system are 
shown to be involved, as altered plasma levels of inflammatory cytokines, chemokines and 
adhesion molecules are found in preeclamptic women [13], both preceding [10, 14] and at 
the time of diagnosis [9].  
 
Tumor necrosis factor (TNF)-α is a potent and multi-functional cytokine produced by 
macrophages, lymphocytes and by trophoblast cells during pregnancy. It is responsible for a 
wide range of proinflammatory actions and its involvement in various autoimmune and 
inflammatory diseases is well documented. Furthermore, it plays an important role in insulin 
resistance and other components of the metabolic syndrome, such as obesity, dyslipidemia 
and endothelial activation [15], which are also common features of PE. Numerous studies 
have found significantly elevated TNF-α concentrations in plasma and amniotic fluid of 
preeclamptic patients [16-27]. In addition, TNF-α protein concentrations and m-RNA 
expression were found to be higher in preeclamptic than normal placentas [28]. Other 
studies have shown the powerful local (autocrine and paracrine) actions, exerted by TNF-α 
at the maternal–fetal interface. Macrophages, residing in excess in the placental bed of 
preeclamptic women, are able to limit extravillous trophoblast invasion of spiral arterial 
segments through apoptosis, mediated by the combination of TNF-α secretion and 
tryptophan depletion [29]. In first trimester villous explant cultures TNF-α inhibits 
trophoblast invasion by induction of plasminogen activator inhibitor-1 (PAI-1) [30]. Finally, 
trophoblast cell integrity may be compromised, resulting in PE, by stimulation of fibrin 
production mediated by TNF-α via up-regulation of prothrombinases [31].  
 
The gene encoding TNF-α lies within the class III region of the major histo-compatibility 
complex (MHC) on the short arm of chromosome 6 (6p21.3). TNF-α 308G/A polymorphism 
lies in the promoter region of the TNF-α gene and was found to be functionally important by 
a number of studies. In vitro the mutant allele A has been associated with higher TNF-a 
production [32], in accordance with studies reporting increased transcriptional activity 
compared to the common (wild type) allele G [33-34]. Furthermore, the –308A TNF-α variant 
has been associated clinically with higher protein levels in various diseases [36-39]. 
However, other studies did not confirm a significant difference in the transcriptional activity 
of mutant allele A and wild type allele G [40, 41].  
 
308G/A was considered to be a variation of great biological significance within the TNF-α 
gene. The underlying hypothesis is that the TNF-α 308G/A polymorphism can influence the 
risk for PE through increased production of TNF-α at the maternal–fetal interface in mutant 
allele carriers. Hence, this SNP has been the subject of numerous studies, which investigated 
its possible association to PE with conflicting results. However, meta-analysis seems to be 
conclusive; no association was found between TNF-α 308G/A polymorphism and risk of PE 
[42-44]. 
 
We proceeded in performing a new meta-analysis on TNF-α 308G/A polymorphism and risk 
of PE for the following reasons: first, there is accumulation of evidence coming from more 
recent gene association studies, which should be evaluated in the context of on-going 
research; second, previous meta-analyses did a limited exploration of the possible genetic 
models of association between TNF-α 308G/A polymorphism and PE, focusing on dominant 
model only or allele contrast; third, subgroup analysis based on disease severity was scarce 
in the relevant bibliography; fourth, subgroup analysis based on ethnicity/racial descent was 
completely lacking.      
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Methods 
Selection of Studies 
All of the studies published before July 2015 were identified by computer based searches of 
MEDLINE and EMBASE data-bases. The following search criterion was used: (“tumor necrosis 
factor” or “TNF” or “cytokine” or “inflammation”) and (“polymorphism” or “single-
nucleotide polymorphism” or “variant” or “mutation” or “genotype” or “haplotype” or 
“gene association study”) and (“preeclampsia” or “gestational hypertension” or “pregnancy 
hypertension” or “HELLP” or “eclampsia”). There was no language limitation. Any clearly 
irrelevant studies, case reports, editorials and review articles were excluded. Duplicate 
publications were considered only once. The remaining articles were carefully read in their 
entity to determine whether they contained information on the topic of interest. All of the 
references cited in the studies were also searched manually to identify additional published 
work not indexed by the MEDLINE and EMBASE databases. 
To be included in the analysis, studies had to meet the following criteria: (1) examination of 
the association between 308G/A TNF-α polymorphism and PE risk; (2) inclusion of both PE 
cases and non-PE controls; (3) patients with clinically confirmed PE; (4) healthy 
normotensive pregnant women or multiparous non-pregnant women with no history of PE 
as controls; (5) inclusion of adequate genotypic data for effect size calculation under all the 
genetic contrasts. Accordingly, the following exclusion criteria were also used: (1) no healthy 
control group; (2) non-conformity with the criteria for PE; (3) control group, not abiding to 
the aforementioned characteristics; (4) full genotype distribution in cases and controls 
unavailable; (5) duplication of previous publications. PE is currently defined as elevated 
blood pressure (≥140/90 mmHg on two different occasions at least 6 hours apart) with 
proteinuria ≥300mg/24h or ‘+’ by dipstick after the 20th week of pregnancy [45]. However, 
other definitions have been used in the past. As long as all cases in a study presented with 
clinically confirmed PE by any definition, which encompasses persistent hypertension with 
quantifiable proteinuria after the 20th week of pregnancy, the study was not excluded. On 
the contrary, if the control group in a study came from the general population or included 
males, the study was excluded. All authors with otherwise eligible studies except for full 
genotype distribution data, were contacted and asked to send the relevant data. Studies, 
whose authors could not be reached, or failed to provide the data after two consecutive 
requests, were finally excluded. When an individual author published several articles 
obtained from the same patient population, only the newest or most complete article was 
included in the analysis. Non conformity of genotype distribution in healthy controls to 
Hardy- Weinberg equilibrium (HWE) was not used as an exclusion criterion. 
Data Extraction 
From each eligible study the following information were extracted using a standardized 
form: first author, journal, year of publication, ethnicity of the study population, 
demographics, diagnostic criteria and clinical characteristics, matching or adjustments made 
for known covariates, genotype method and the number of cases and controls for each 
308G/A TNF-α genotype. The frequencies of the alleles and the genotypic distributions were 
extracted or calculated for both the cases and the controls. In addition, it was recorded 
whether the genotyping in each study was blinded to clinical status. An attempt was made 
to contact authors if data presentation was incomplete or if it was necessary to resolve an 
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apparent conflict or inconsistency in the article. After that, any remaining cases of conflicting 
evaluations or disagreements on inconsistent data from the eligible studies were resolved 
through careful reexamination of the full text by the author.    
Meta-Analysis 
Allele frequencies at TNF-α 308G/A polymorphism from each study were calculated by the 
allele counting method. HWE was assessed in control groups of each study using the 
goodness-of fit test (chi-square test), which was considered significant for p<0,05 [46]. 
Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of 
association between the TNF-α 308G/A polymorphism and the risk of PE in allele contrast (A 
vs G) and dominant, co-dominant, recessive and additive genetic models. Based on the 
individual ORs, a pooled OR was estimated using fixed effects (FEs, Mantel-Haenszel) and 
random effects (REs, DerSimonian and Laird) models [47]. Heterogeneity was measured 
using Cochran’s Q test and    statistic, which reflects the percentage of total variation across 
studies that is due to heterogeneity rather than due to chance [48]. The corresponding p-
value of the Q statistic below 0,05 or   > 50% was considered significant heterogeneity. RE 
modelling assumes a genuine diversity in the results of various studies and incorporates to 
the calculations a between-study variance. Therefore, when there is significant 
heterogeneity between studies, the pooled OR deriving from the RE model is more valid.  
 
The publication bias of studies for all the genetic contrasts under investigation was assessed 
using Egger’s regression tests for funnel plot asymmetry [49]. Given that this test is 
underpowered, it was considered statistically significant for p<0,10 rather than for p<0,05.  
The main or overall analysis included all the available data on PE, severe preeclampsia (SPE) 
and eclampsia (E). Based on disease severity additional subgroup analysis was conducted. 
Studies addressing only SPE were analyzed as a subgroup. Data on eclamptic patients were 
also analyzed separately and finally another analysis incorporated data on both SPE and E 
(SPE/E). Subgroup analysis by ethnicity/racial descent for Caucasians and African Americans 
was also performed. For the subgroup analysis by ethnicity/racial descent the relevant data 
were only used when stated clearly by the authors, and not assumed by the geographic 
position of the study. 
A sensitivity analysis was conducted excluding all studies considered of questionable quality. 
Deviation from HWE of genotypes distribution in controls was the main, but not the sole, 
reason for marking a study as of questionable quality. An additional sensitivity analysis 
examined the effect of the largest studies in the meta-analysis results, excluding them one 
by one.    
Statistical analyses were performed by Review Manager 5.1 by the Cochrane Library, 
Microsoft Excel 2013 (Microsoft, Redmond, Washington, USA) and IBM SPSS Statistics for 
Windows, Version 21.0 (IBM Corp., Armonk, NY, USA).  
Results 
Characteristics of eligible studies 
A total of 170 articles relevant to the searched keywords were initially identified. There was 
no language limitation, however all the obtained results were in English. Of these articles, 30 
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were selected as potentially relevant studies after reading the titles and abstracts [50-59, 61-
67, 69-81]. Full texts were then reviewed for a more detailed evaluation. Searching the 
reference lists produced 2 more potentially relevant studies [60, 68]. The main reasons for 
exclusion were as follows: 4 papers proved to be irrelevant studies [50-53], 4 studies 
included cases of both PE and gestational hypertension [54-57], 1 paper was a duplicate 
publication [58], 2 studies did not provide any genotype data [59-60] and finally in 4 studies 
a full genotype distribution in cases and controls was not retrieved after attempted contact 
with the authors [61-64]. From the latter 4, in one study the controls came from the general 
population, male and female [61] and another [62] was partially duplicated in a newest 
article [76]. 17 studies met the inclusion criteria and were included in this meta-analysis. 2 
articles provided data on 2 separate study ethnicities: Caucasians and African Americans. 
Thus data were obtained from 19 studies. The study selection process is shown in Figure1.  
 
Figure 1. Flow chart of retrieved studies and studies excluded, with specification of reasons.  
10 articles included cases with PE [65, 68-70, 72, 75, 77-80]. 3 articles were restricted to SPE 
[66, 73, 81]. 3 articles included distinct cases of PE and E [67, 71, 76]. In the former studies E 
by definition presupposed PE, so these cases were included in the main analysis. If a study 
included HELLP syndrome cases indistinctly in the PE group, these were also included in the 
main analysis. However, only 1 study presented with a distinct HELLP group [74]. It was not 
stated whether these patients also fulfilled diagnostic criteria for PE. Moreover, the author 
himself did not include these patients in his meta-analysis on PE. Thus, we have excluded 
these patients. 10 studies clearly stated the common racial descent of cases and controls: 8 
involved Caucasians [67-70a, 73, 74, 79a, 80], 2 involved African Americans [70b, 79b], 1 
involved Maya-Mestizo [72], 1 involved Mexican Mullato [76]. The rest of the studies were 
set in Iran [75, 78], Turkey [71, 77], Brazil [81], UK [65] and USA [66]. The design was case-
control in most of the studies. Exceptions were: a prospective cross-sectional study [66], a 
study nested in a cohort [79] and a study with two arms, longitudinal cohort and cross-
sectional [70].  DNA samples used for determination of the TNF-α polymorphism were  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:09:02 EET - 137.108.70.7





















Severe PE: SBP≥160 mmHg or DBP ≥110 mmHg on two occasions 










SBP≥140 mmHg or DBP ≥90 mmHg on two occasions at least 6 h 
apart and proteinuria ≥300mg/24h or persistent ‘++’ by dipstick 
(51 cases with E, diagnosed in severe preeclamptic women 










DBP ≥90mmHg on two occasions at least 4 h apart with 










SBP≥140 mmHg or DBP ≥90 mmHg on two occasions at least 24 h 










BP≥140/90 mmHg on two occasions with proteinuria ≥300mg/24h 










BP≥140/90 mmHg on two occasions with proteinuria ≥300mg/24h 









BP≥140/90 mmHg on two occasions at least 24 h apart with 
proteinuria ≥300mg/24h or persistent ‘++’ by dipstick 
(40 cases with E, diagnosed in severe preeclamptic women 




















SBP≥160 mmHg or DBP ≥110 mmHg on two occasions at least 4 h 



















SBP≥140 mmHg or DBP ≥90 mmHg on two occasions at least 24 h 









Persistent BP≥140/90 mmHg with proteinuria ≥300mg/24h 
(64 cases with eclampsia, defined as otherwise unexplained 








SBP≥140 mmHg or DBP ≥90 mmHg on two occasions at least 6 h 


















Gestational hypertension (defined as SBP≥140 mmHg or DBP ≥90 










Gestational hypertension (defined as SBP≥140 mmHg or DBP ≥90 









SBP≥140 mmHg or DBP ≥90 mmHg on two occasions at least 6 h 









Severe PE: SBP≥160 mmHg or DBP ≥110 mmHg on two occasions 





Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:09:02 EET - 137.108.70.7
extracted from blood. Instead, smears from buccal gingival cells were used in only 1 study 
[73]. Only 1 study stated that genotyping was blinded to clinical status [73].  
The quality of the included studies was assessed on the basis of 5 characteristics: 1) selection 
criteria for cases; 2) selection criteria for controls; 3) conformity of controls with HWE; 4) 
level of exclusion of confounding factors; 5) genotyping method. In all but one studies, 
participants fulfilled generally accepted criteria for PE, SPE and E. Only in 1 study the 
description of cases was deemed inadequate [78]. Controls were normotensive pregnant 
women in most of the studies and multiparous non-pregnant women with no history of PE in 
1 study [77]. 2 studies, however included two groups of controls: normotensive pregnant 
women and normotensive non pregnant women [65, 81]. As the obstetrical history of these 
latter non-pregnant controls was not stated, we chose not to include them in this meta-
analysis. The distribution of genotypes in the control group deviated from HWE in 2 studies 
[66, 75]. However, the corresponding p-value was marginally non-significant in other 3 
studies [72, 77, 80]. Some studies included only primigravidae women to match for parity 
[67, 68, 69, 70, 71, 73]. Matching of cases and controls  included gestational age [66, 78], 
maternal age [77], maternal age, gestational age, BMI, month of year at delivery [68], 
maternal age, educational level, smoking [73]. 3 studies implemented statistical adjustment 
to control for maternal age, BMI, primiparity [74], maternal age, smoking, education [70], 
maternal age, smoking, BMI, parity, socioeconomic status [79], which did not change the 
pattern of their results. Moreover, these latter 2 studies stratified data by race. In 6 studies 
there is no description of specific actions taken to exclude confounding factors [65, 72, 75, 
76, 80, 81]. Validated genotyping methods were used in all of the studies; namely, PCR- RFLP 
[66, 67, 69, 71, 72, 74, 77, 78, 80], PCR with allele-specific probes [68, 75, 76, 81], 
quantitative PCR [65], real-time PCR [70], microarrays [73] and custom GoldenGate 
Genotype Assay [79]. A sensitivity analysis was performed excluding all studies considered as 
of low quality according to the aforementioned characteristics [65, 66, 72, 75, 77, 80]. 
Detailed characteristics of the included studies are summarized in Table 1 and Table 2.  
Main Results, Subgroup and Sensitivity Analyses 
Overall, the ORs and 95% CIs of PE risk were considered under allele contrast (A vs G) and 
dominant, co-dominant, recessive and additive genetic models. A summary of all the meta-
analysis findings of the associations between TNF-α 308G/A polymorphism and PE risk is 
provided in Table 3.  
A total of 5654 subjects from 19 (17) studies were involved in the main analysis, including 
2042 PE cases and 3612 controls. The meta-analysis results showed that TNF-α 308G/A 
polymorphism was not linked to the risk of PE under any genetic model (RE OR: 1,20, 95% CI: 
0,90 to 1,58 under the dominant model). Nonsignificant heterogeneity among studies was 
found only under the additive and the recessive model (P=0,39;   =23% and P=0,71;   =0% 
respectively). Main analysis results are also presented in Figure 2.  
490 cases and 597 controls, 1087 subjects in total, from 6 studies, were included for data 
synthesis regarding the TNF-α 308G/A polymorphism and its relationship to SPE/E. The 
association was not significant under any genetic model (RE OR: 1,10, 95% CI: 0,65 to 1,87 
under the dominant model). Only the additive and recessive models showed nonsignificant 
heterogeneity among studies (P=0,48;   =0% and P=0,71;   =0% respectively). 655 subjects 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:09:02 EET - 137.108.70.7
TABLE 2. The distribution of the 308G/A TNF-α genotype for cases and controls (in parenthesis are the 
respective percentages). 
 
in total, 335 cases and 320 controls, from 3 studies, were included for data synthesis on TNF-
α 308G/A polymorphism and risk of SPE. Again, no association was found (FE OR: 1,03, 95% 
CI: 0,69 to 1,54 under the dominant model). However heterogeneity was not significant in all 
but one the genetic contrasts (P=0,37;   =0% under the dominant model). For E, a total of 
432 subjects, 155 cases and 277 controls, from 3 studies, were included for data synthesis. 
The meta-analysis did not produce any significant association (RE OR: 1,49, 95% CI: 0,45 to 
4,93 under the dominant model). Nonsignificant heterogeneity among studies was found 
only under the additive and the recessive model (P=0,40;   =0% and P=0,64;   =0% 
respectively). Subgroup analysis results based on disease severity (SPE/E, SPE, E) are also 
presented in Figure 3.  
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Table 3. ORs and heterogeneity results for the genetic contrasts of 308G/A TNF polymorphism for PE 
(main analysis, sensitivity analysis for poor quality of studies, subgroup analysis based on 
ethnicity/racial descent and disease severity).  
 
Subgroup analysis based on ethnicity/racial descent included 3108 Caucasians, 1005 cases 
and 2103 controls, from 8 studies, and 752 African Americans, 90 cases and 662 controls, 
from 2 studies. For African Americans heterogeneity among studies was not significant 
(P=0,55;   =0% under the dominant model) and no association was found (FE OR: 0,61, 95% 
CI: 0,34 to 1,10 under the dominant model). In Caucasians, the subgroup analysis results 
showed that the TNF-α 308G/A polymorphism was linked to the risk of PE under the 
dominant and co-dominant models (FE OR: 1,47, 95% CI: 1,23 to 1,77, dominant model; FE 
Genetic Contrast/ 
Model 
Population FE OR (95% CI) RE OR (95% CI) Stu- 
dies 




A vs G All 0,99 (0,82 to 1,21) 1,05 (0,75 to 1,47) 19 64,4% <0.01 
Allele frequencies Sensitivity 0,95 (0,76 to 1,17) 1,01 (0,68 to 1,50) 13 68,7% <0.01 
 Caucasians 1,30 (0,99 to 1,71) 1,30 (0,99 to 1,71) 8 0% 0,57 
 African Americans 0,66 (0,34 to 1,25) 0,66 (0,34 to 1,25) 2 0% 0,50 
 SPE/E 0,87 (0,78 to 0,97) 0,91 (0,67 to 1,24) 6 85% <0.01 
 SPE 0,83 (0,71 to 0,97) 0,78 (0,56 to 1,09)  3 75% 0,02 
 E 0,92 (0,78 to 1,08) 1,13 (0,60 to 2,11) 3 92% <0.01 
Dominant All 1,22 (1,05 to 1,41) 1,20 (0,90 to 1,58) 19 68% <0.01 
AA, GA vs GG Sensitivity  1,29 (1,10 to 1,51) 1,27 (0,96 to 1,69) 14 65% <0.01 
 Caucasians 1,47 (1,23 to 1,77)* 1,46 (1,17 to 1,84)* 8 32,6% 0,16 
 African Americans 0,61 (0,34 to 1,10) 0,61 (0,34 to 1,10) 2 0% 0,55 
 SPE/E  1,09 (0,81 to 1,46) 1,10 (0,65 to 1,87) 6 65% 0,01 
 SPE 0,93 (0,64 to 1,36) 0,93 (0,64 to 1,36) 3 0% 0,37 
 E 1,39 (0,87 to 2,22) 1,49 (0,45 to 4,93)  3 81% <0.01 
Co-Dominant All 1,22 (1,05 to 1,42) 1,21 (0,93 to 1,59) 19 62,9% <0.01 
GA vs GG, AA Sensitivity 1,29 (1,10 to 1,51) 1,27 (0,98 to 1,66) 13 58% <0.01 
 Caucasians 1,43 (1,18 to 1,73)* 1,43 (1,14 to 1,78)* 8 29% 0,19 
 African Americans 0,70 (0,39 to 1,26) 0,70 (0,39 to 1,26) 2 0% 0,65 
 SPE/E 1,16 (0,85 to 1,58) 1,16 (0,71 to 1,92) 6 57% 0,04 
 SPE 1,03 (0,69 to 1,54) 1,03 (0,69 to 1,54) 3 0% 0,61 
 E 1,37 (0,85 to 2,21)  1,45 (0,45 to 4,70)  3 79% <0.01 
Additive All 1,14 (0,76 to 1,70) 1,11 (0,73 to 1,70) 19 23% 0,39 
AA vs GG Sensitivity 1,15 (0,74 to 1,79) 1,08 (0,63 to 1,83) 13 23% 0,23 
 Caucasians 1,43 (0,87 to 2,34) 1,39 (0,79 to 2,45) 8 19,5% 0,27 
 African Americans 0,66 (0,08 to 5,50) 0,68 (0,06 to 6,95) 2 17,3% 0,27 
 SPE, E  0,64 (0,29 to 1,44) 0,68 (0,30 to 1,55) 6 0% 0,48 
 SPE 0,39 (0,14 to 1,13) 0,39 (0,14 to 1,13) 3 0% 0,92 
 E 1,50 (0,41 to 5,52) 1,58 (0,42 to 5,91)  3 0% 0,40 
Recessive All 1,15 (0,78 to 1,70) 1.15 (0,78 to 1,70) 19 0% 0,71 
AA vs GG, GA Sensitivity 1,19 (0,77 to 1,84) 1,28 (0,82 to 2,00) 13 0% 0,45 
 Caucasians 1,42 (0,87 to 2,31) 1,42 (0,87 to 2,31) 8 0% 0,50 
 African Americans 0,70 (0,086 to 5,79) 0,72 (0,075 to 6,98) 2 13,3% 0,28 
 SPE/E 0,60 (0,27 to 1,34) 0,62 (0,27 to 1,40) 6 0% 0,71 
 SPE 0,39 (0,14 to 1,12) 0,39 (0,14 to 1,13) 3 0% 0,94 
 E 1,22 (0,34 to 4,41)  1,23 (0,34 to 4,51)  3 0% 0,64 
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OR: 1,43, 95% CI: 1,18 to 1,73, co-dominant model). It is to be underlined that in this 
subgroup the heterogeneity among studies was not significant in any case (P=0,16;   =32,6%  
Figure 2. RE OR estimates with the corresponding 95% CI for the dominant (A), co-dominant (B), 
recessive (C) and additive (D) models of TNF 308G/A polymorphism allele A and the risk of PE. 
 A 
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Figure 2. (continued) 
  D 
 
 
and P=0,19;   =29% for dominant and co-dominant model respectively). Subgroup analysis 
results for Caucasians are also presented in Figure 4. 
Sensitivity analysis excluding studies of poor quality and sensitivity analysis excluding one by 
one the largest studies did not alter the pattern of results in the main analysis and the 
subgroup analyses under any contrast.  
Potential Bias 
Begg’s funnel plot and Egger’s tests were performed for all the genetic models under 
investigation in order to assess the publication bias of included studies (Figure 5). The 
shapes of the funnel plots did not reveal any evidence of obvious asymmetry under the co-
dominant, recessive and additive model. Egger’s test did not show any significantly statistical 
evidence of publication bias under any contrast (dominant model, p= 0,57; co-dominant 
model, p= 0,85; recessive model, p= 0,12; additive model, p= 0,17). Furthermore, the 
possibility for subgroup-specific publication bias was assessed for Caucasians under the 
dominant model (Egger’s test, p=0,91). Thus, it can be assumed that the risk of publication 
bias in this meta-analysis is low.   
Discussion 
This meta-analysis examined the TNF-α 308G/A polymorphism and its relation to 
susceptibility for PE. The strength of the present analysis was based on the accumulation of 
published data giving greater information to detect significant differences. In the present 
study, the effect of allele frequency and the effects of the dominant, co-dominant, additive 
and recessive models were estimated. Much of this work has been presented for the first 
time. Disease severity in PE was taken into account, in our attempt to form less 
heterogeneous groups that would to lead us to more consistent results. In addition, the 
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consistency of genetic effects across populations with different ethnicity/racial descent was 
investigated, also for the first time to our knowledge.  









Our overall analysis results are consistent with previous meta-analysis [42-44], which failed 
to associate TNF-α 308G/A polymorphism with PE risk. SPE and E patients theoretically 
represent a more homogeneous group. However, TNF-α 308G/A polymorphism does not 
seem to affect the risk for SPE/E, SPE or E either. This result, too, is in accordance with 
previous, eventhough less extended, meta-analysis, which found no association between 
TNF-α 308G/A polymorphism and SPE/E risk [42]. Subgroup analysis based on 
ethnicity/racial descent, performed for the first time, revealed an association between TNF-
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α 308G/A polymorphism and risk of PE in Caucasians. Moreover, within this subgroup 
heterogeneity among studies was invariably nonsignificant. The result was robust to  
Figure 4. TNF 308G/A polymorphism and risk for PE. Subgroup analysis for Caucasians based on the 
dominant model (A), with sensitivity analysis for poor quality of studies (B) and sensitivity analysis for 







sensitivity analysis. Furthermore, it is unlikely that publication bias is the underlying cause of 
the positive association found.  
Eventhough no individual study has an excessive effect on the subgroup analysis results, the 
positive association within the subgroup of Caucasians is due in the greatest part to the 
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presence of 2 studies [70, 79].  Both of them are set in USA, provide a large sample, 
stratified by race, and are characterized by a strict methodology. Each of them, individually, 
found the risk for PE to be increased in Caucasians carriers of the A allele. Neither detected 
the same association for African Americans. Furthermore, in both studies the results were 
unaffected by statistical adjustment for known covariates, such as maternal age and 
smoking. It is unclear why distinctive association patterns emerged for African Americans 
and Caucasians; it may reflect distinct phenotypes, or possibly interactions with social or 
environmental exposures that are differentially distributed across these two populations 
[79]. However, a number of studies can support the hypothesis that known differences in 
clinical manifestations between various ethnic groups, such as PE prevalence [1], are due in 
part to inheritance of cytokine polymorphism. Differences of the allelic frequency in TNF-α 
308G/A polymorphism and other genes associated with inflammation have been reported 
among diverse geographically distributed populations [82] and among Whites and African 
Americans in the United States [83]. Moreover, regulation of TNF-α levels during pregnancy 
appears to differ between White and African American women [84]. Thus, the claim that 
patterns of cytokine concentrations, as well as the genetic regulation of these 
concentrations, may be different between these two latter groups [85] would be in 
accordance with our results. Concluding, it is high likely that our findings represent a true 
association and the risk for PE among Caucasians, who carry the A allele in the TNF-α 
308G/A polymorphism is indeed elevated.  
 
Although there is a strong genetic contribution to PE, other complex mechanisms and 
environmental interactions play a significant role in its pathogenesis. Maternal and fetal 
genes interacting with each other (and a variety of environmental stimuli) interfere on PE 
severity and outcome. Interactions between genetic susceptibility and environmental 
exposures such as smoking, infections, nutrition, or exposure to environmental toxicants 
contribute to the heterogeneity of phenotypes seen in PE [70].  Thus, it is difficult to define 
genetic variants, which consistently and significantly contribute to PE. Indeed, the effect of 
various gene polymorphisms on PE, estimated in gene association studies, appears to be 
small as evidenced by the reported ORs. The repeatability of the results is also poor across 
different ethnic groups. Therefore, gene polymorphisms explored so far through on-going 
research have not gained a role in the clinical prediction of PE. Considering the important 
environmental and lifestyle modifiable risk factors for PE, it will be interesting to investigate 
potential gene–gene and gene-environment interactions in genes associated with PE. Per 
example, there is considerable evidence that inflammation may be part of the casual 
pathway through which obesity predisposes to preeclampsia [86]. Elevated body fat may 
trigger excessive cytokine production among genetically susceptible pregnant women [87].  
 
It is well documented that women who have had pre-eclampsia are more likely to develop 
cardiovascular disease, and pre-eclampsia and cardiovascular disease share various risk 
factors, including obesity, hypertension and diabetes [1]. The shared risk factors for both 
pre-eclampsia and later-life vascular diseases, as well as the familial segregation of all these 
disorders suggest that these diseases share a common genetic predisposition that interacts 
with the environment and may predispose individuals to vascular disorders which manifest 
at different time points throughout the life course. Prospective cohort studies collecting data 
on relevant clinical, environmental and lifestyle risk factors coupled with longitudinal 
measurement of angiogenic, inflammatory factors and genetic variations in candidate genes 
will be able to determine high risk populations and provide information useful in the clinical 
prediction of PE.  
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Our meta-analysis has several limitations, which should be taken into account. First, 
eventhough our main analysis is not underpowered, lack of sufficient statistical power for 
some outcomes may still be encountered in subgroup analysis, due to the relatively small 
sample size used. Second, meta-regression analysis to further control for known  
Figure 5. Funnel plots of SE against the log OR for the association between 308G/A TNF polymorphism 
and risk of PE. (A) Dominant model (Egger test: t= 0,58, p= 0,57), (B) Co-dominant model (Egger test: 
t= 0,19, p= 0,85), (C) Recessive model (Egger test: t= 1,61,  p=0,12), (D) Additive model (Egger test: t= 
1,40, p= 0,17). 
A                                       B 
 
  C                                       D 
    
 
confounders was not undertaken in our study due to the lack of relevant data. Smoking, 
maternal weight, maternal age, parity and other clinical covariates were not considered by a 
great number of studies. Such problems, if inherent in the included studies, remain unsolved 
after meta-analysis. Third, PE is believed to result from a complex interplay between genetic 
components, maternal and fetal genes interacting with each other, and environmental 
factors. It was impossible to incorporate to our analysis the small amount of data regarding 
the involvement of fetal genes in PE risk, disease severity and outcome. Similarly, although 
some of the studies reported on haplotypes, we did not include these data to our analysis. 
None of the studies explored gene-environment interactions. Fourth, since some studies 
were not considered in our analysis due to methodological reasons, we can’t tell whether 
inclusion of their data would have altered our findings, especially the result of subgroup 
analysis for Caucasians. 
 
As a conclusion, the present meta-analysis aimed to update the previous meta-analyses, as 
well as to provide a more comprehensive and reliable conclusion on the association 
between the TNF-a 308G/A polymorphism and risk of PE. Although TNF-a 308G/A 
polymorphism was not overall significantly associated with PE, SPE or E, its role in PE 
susceptibility needs to be reevaluated, as it may account for increased risk for PE in 
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Caucasians. The complexity of TNF-α regulation and apparent heterogeneity based on 
ethnicity/racial descent support further investigation into this gene. However, future studies 
need to focus in determining high risk populations, based on a plurality of characteristics, 
taking into account genetic, environmental and socioeconomic effects.  
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